Imlunestrant tosylate (Synonyms: LY-3484356 tosylate)
目录号: PL04097 纯度: ≥98%
CAS No. :2408840-41-3
商品编号 规格 价格 会员价 是否有货 数量
PL04097-5mg 5mg ¥14218.18 请登录
PL04097-10mg 10mg 询价 询价
PL04097-50mg 50mg 询价 询价
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Imlunestrant tosylate
英文名称
Imlunestrant tosylate
英文别名
UNII-F7UDT90EW5;LY-3484356 TOSYLATE;MS-31158;LY-3484356 TOSILATE;Imlunestrant tosylate [USAN];(5R)-5-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-8-(trifluoromethyl)-5H-(1)benzopyrano(4,3-c)quinolin-2-ol, tolysate salt (1:1);LY3484356 TOSILATE;2408840-41-3;LY-3484356 (tosylate);LY3484356 TOSYLATE;Imlunestrant (tosylate);Imlunestrant tosylate;IMLUNESTRANT TOSILATE;F7UDT90EW5;(R)-5-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-2-ol 4-methylbenzenesulfonate
Cas No.
2408840-41-3
分子式
C36H32F4N2O6S
分子量
696.71
包装储存
4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
产品详情
Imlunestrant (LY-3484356) tosylate 是一种口服有效的和选择性的雌激素受体(estrogen receptor) 降解剂 (SERD),具有纯拮抗特性。Imlunestrant tosylate 可持续抑制 ER 依赖基因转录和细胞生长。Imlunestrant tosylate 可用于 ER 阳性 (ER+) 晚期乳腺癌 (aBC) 和子宫内膜内膜样癌 (EEC) 的研究。
生物活性
Imlunestrant (LY-3484356) tosylate is an orally active, potent and selective estrogen receptor degrader (SERD) with pure antagonistic properties. Imlunestrant tosylate results in sustained inhibition of ER-dependent gene transcription and cell growth. Imlunestrant tosylate can be used for the research of ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC).
性状
Solid
体外研究(In Vitro)
LY3484356 显示出良好药代动力学 (PK) 特性,包括在 ESR1 突变体中的抗肿瘤活性。 has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
参考文献
[1]. Komal L. Jhaveri, et al. A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study. 2021 ASCO Annual Meeting I.
[2]. Cristina Hernando, et al. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. Int. J. Mol. Sci. 2021, 22(15), 7812.
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2